The US Food and Drug Administration (FDA) has issued a warning against the use of 26 over-the-counter eye drop products.

The regulator asked consumers not to buy and to immediately stop using the products due to the risk of infections that could lead to partial vision loss or even blindness.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Patients who have used the products should consult their healthcare provider or seek medical advice. 

The medicines are offered under the brand names CVS Health, Leader (Cardinal Health), Rite Aid, Rugby (Cardinal Health), Target Up&Up and Velocity Pharma.

On 25 October 2023, the FDA recommended manufacturers to recall all the lots after regulatory investigators detected unsanitary conditions at manufacturing sites. 

The investigators found positive results from bacterial tests conducted on samples taken at critical drug manufacturing areas. 

The regulator asked consumers to carry out product disposals properly.

In a press statement, the FDA noted: “CVS, Rite Aid and Target are removing the products from their store shelves and websites. 

“Products branded as Leader, Rugby and Velocity may still be available to purchase in stores and online and they should not be purchased.”

The FDA has not yet received reports of adverse events linked to the products’ usage.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact